Kiniksa Pharmaceuticals International, plc (KNSA)

77.91USD -3.18% (-2.56)

Over 1M: +2.4%

Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

76 78 80
7 Aug 12 Aug 17 Aug 20 Aug 25 Aug 28 Aug 2 Sep

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q2 '25 — Revenue: 156.8M Q2 '25 — Operating Income: 20.2M Q2 '25 — Free Cash Flow: 27.9M Q3 '25 — Revenue: 180.9M Q3 '25 — Operating Income: 24M Q3 '25 — Free Cash Flow: 33M Q4 '25 — Revenue: 202.1M Q4 '25 — Operating Income: 19.8M Q4 '25 — Free Cash Flow: 53.3M Q1 '26 — Revenue: 214.3M Q1 '26 — Operating Income: 29.3M Q1 '26 — Free Cash Flow: 50M 0 50M 100M 150M 200M 250M
Q2 '25 Q3 '25 Q4 '25 Q1 '26
Revenue Operating Income Free Cash Flow

How it scores

For a valuation multiple, the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

6.1
ROIC 53.5%
OE margin 16.6%
Oper. margin 12.4%
Accruals -11.2%
Gross margin 89.3%
ROA 8.9%
FCF margin 21.8%
OCF / EBIT 1.8×
OCF margin 22.0%
ROCE 13.9%
ROE 12.1%

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

3.6
EV/OE 47.7×
EV/EBIT 63.9×
P/C 13.7×
FCF yield 2.6%
EV/Sales 7.9×
P/B 10.6×
P/E 87.9×
Div. yield —
EV/GP —
Fwd P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

4.3
RPO / sales —
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

10.0
ND/EBITDA 0.079
Interest cover —
Debt / Eq 0.0×
Debt payback 0.0 yr
F-score 7.9 pts
Payout 0.0%
Quick ratio 3.3×
Cash / Debt —
Cash runway —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

8.7
Sales CAGR 4Y +104.8%
Sales/sh Y/Y +41.7%
EBIT CAGR +100.3%
Sales Q/Q +55.5%
Shares change +10.6%
Div. growth —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.